C12N 15/1136
Against growth factors, growth regulators, cytokines, lymphokines or hormones
Official title: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
C12N15/1136 (Against growth factors, growth regulators, cytokines, lymphokines or hormones) appears on 931 US grants and 1,789 published applications in this corpus.
Search patents in C12N- Granted patents
- 931
- Published applications
- 1,789
- Assignees
- 696
- Inventors
- 2,747
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 21 | 0 |
| 1998 | 21 | 0 |
| 1999 | 15 | 0 |
| 2000 | 25 | 0 |
| 2001 | 14 | 1 |
| 2002 | 22 | 20 |
| 2003 | 6 | 39 |
| 2004 | 7 | 38 |
| 2005 | 6 | 46 |
| 2006 | 8 | 47 |
| 2007 | 8 | 42 |
| 2008 | 8 | 68 |
| 2009 | 24 | 79 |
| 2010 | 40 | 95 |
| 2011 | 41 | 69 |
| 2012 | 40 | 66 |
| 2013 | 38 | 58 |
| 2014 | 44 | 89 |
| 2015 | 52 | 99 |
| 2016 | 63 | 86 |
| 2017 | 53 | 87 |
| 2018 | 62 | 95 |
| 2019 | 42 | 73 |
| 2020 | 60 | 87 |
| 2021 | 50 | 95 |
| 2022 | 35 | 79 |
| 2023 | 31 | 80 |
| 2024 | 30 | 84 |
| 2025 | 24 | 91 |
| 2026 | 38 | 76 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Compositions and methods for inhibiting ANGPTL3 expression15 Sep 2026US 12,735,710 B2Dicerna Pharmaceuticals, Inc.
- Composition for regulating production of interfering ribonucleic acid8 Sep 2026US 12,729,380 B2Wyvern Pharmaceuticals Inc.
- Cystic lymphangioma treatment drug4 Aug 2026US 12,698,324 B2National University Corporation University of Toyama
- CTGF gene-specific double-stranded oligonucleotide, and a composition for preventing and treating fibrotic diseases and respiratory-related diseases comprising same4 Aug 2026US 12,698,500 B2Bioneer Corporation
- Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome1 Oct 2026US 2026/0297180 A1
- Gip activity modulators and orthostatic intolerance24 Sep 2026US 2026/0285992 A1Antag Therapeutics ApS
- Pharmaceutical composition comprising sclerostin inhibitor as active ingredient for prevention or treatment of diabetic eye disease24 Sep 2026US 2026/0286362 A1Chung Ang University Industry Academic Cooperation Foundation
- Extracellular vesicle comprising a biologically active molecule and a cleavable linker10 Sep 2026US 2026/0263626 A1Lonza Sales AG
- Use of anti-fam19a5 antagonists for treating hearing disorders10 Sep 2026US 2026/0265360 A1Neuracle Science Co., Ltd.
Most cited
By later US patents
- Oligonucleotide therapeutic agent and method of making same726US 5,023,243 AMolecular Biosystems, Inc. · 1991
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- Functional and hyperfunctional siRNA230US 7,691,997 B2Dharmacon, Inc. · 2010
- Functional and hyperfunctional siRNA178US 8,090,542 B2Dharmacon, Inc. · 2012
- Methods and compositions involving miRNA and miRNA inhibitor molecules171US 9,506,061 B2Asuragen, Inc. · 2016